Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Stock Jumps 6.6 Percent on Positive Study in Postmenopausal Women

NEW YORK (GenomeWeb News) — Shares in Genomic Health were up 6.56 percent, or $1.26, at $20.47 in mid-afternoon trading after the company this morning said its Oncotype DX showed positive results in predicting the likelihood of recurrent breast cancer in postmenopausal women.
The test is currently used to predict recurrence and the likelihood of benefit from chemotherapy in women with estrogen-receptor positive, node-negative breast cancer.
The study in postmenopausal women, conducted by the Southwest Oncology Group, a National Cancer Institute clinical trials cooperative group, will be submitted for presentation at the 30th Annual San Antonio Breast Cancer Symposium in December.
According to a report in the Associated Press, Cantor Fitzgerald analyst George Zavoico said the new indication, if approved, would increase the number of patients eligible for the test annually by as much as 20 percent, or between 125,000 and 145,000 from between 100,000 and 120,000.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.